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Background: Inhalation of swine house dust induces acute airway inflammation and
increased bronchial responsiveness in healthy subjects.
Objective: The aim of the study was to investigate whether 5-lipoxygenase products
such as leukotrienes may have a role in this reaction.
Methods: Twenty-three healthy subjects were randomised into two groups receiving
treatment with either zileuton (600mg) or placebo four times a day. After 5 days of
treatment, all subjects were exposed for 3 h in a swine barn. Bronchial
responsiveness, exhaled nitric oxide (NO), and mediators in nasal lavage (NAL),
blood and urine were measured before and after the exposure.
Results: The exposure induced an increased bronchial responsiveness to methacho-
line in both groups with 2–3 doubling concentration steps, no significant difference
between treatments. Leukotriene E4 in urine increased significantly following
exposure in the placebo group from 37.3 (29.1–45.6) (mean (95% confidence
interval)) ng/mmol creatinine to 47.7 (36.3–59.0) ng/mmol creatinine (Po0:05), but
not in the zileuton group. The post-exposure increase of LTB4 levels in NAL fluid was
totally abolished in the zileuton group (Po0:05 vs. the placebo). The levels of
exhaled NO increased significantly (Po0:01), two-fold in both groups. The PGD2
metabolite 9a, 11b-PGF2 increased in placebo-treated subjects (Po0:01; Po0:05 vs.
zileuton), strengthening mast cell participation. Neutrophil counts and levels of IL-6
in peripheral blood increased in both groups, with a significantly larger increase in
zileuton treated subjects (Po0:05 and Po0:001, respectively compared to placebo).Elsevier Ltd. All rights reserved.
24 822 10; fax: +46 8 30 06 19.
m.ki.se (L. Palmberg).
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Effects of 5-lipoxygenase inhibitor zileuton on airway responses 227Conclusions: Pre-treatment with clinically recommended doses of the 5-lipoxygen-
ase inhibitor zileuton did not affect the increase of bronchial reactivity induced by
swine dust exposure. The intervention totally abolished the LTB4 release in NAL fluid,
but only partially inhibited the formation of leukotrienes as monitored by urinary
levels. The enhanced increase of neutrophils and IL-6 in peripheral blood in the
zileuton group, suggests that inhibition of 5-lipoxygenase may have pro-inflamma-
tory effects.
& 2005 Elsevier Ltd. All rights reserved.Introduction
A standardised exposure to swine house dust has
been well documented to induce pulmonary in-
flammation associated with a marked increase in
bronchial responsiveness to methacholine in
healthy, previously unexposed subjects.1–3 As the
inflammatory response has several similarities to
the inflammation observed in patients with chronic
bronchitis and chronic obstructive pulmonary dis-
ease (COPD)4 as well as the reaction following
exposure to tobacco smoke,5 this particular model
may, in addition to its direct bearing on occupa-
tional medicine, provide insights into mechanisms
of relevance to chronic bronchitis and/or COPD.
Thus, the post-exposure increase of bronchial
responsiveness is associated with an intense in-
flammatory response characterised by a prominent
neutrophilia and increased levels of cytokines such
as interleukin-6 (IL-6), IL-8 and tumour necrosis
factor-a (TNF-a) in the upper and lower airways.6–8
The mechanisms of the increased bronchial respon-
siveness remain unknown, and the relation be-
tween the observed inflammatory response and the
changes in bronchial responsiveness is another area
of uncertainty. Previous results with increased
urinary excretion of the prostaglandin (PG) D2
metabolite 9a, 11b-PGF2 have strongly indicated
mast cell activation following swine house dust
exposure.3 Exhaled nitric oxide (NO) has been
found to be increased in many inflammatory
airways diseases such as asthma13 and chronic
bronchitis,14 and there are experimental data
supporting direct interactions between NO and
the 5-lipoxygenase (LO) pathway.15
We have earlier reported that exposure to swine
house dust was associated with increased urinary
excretion of leukotriene E4 (LTE4) and increased
levels of LTB4 and LTE4 in nasal lavage (NAL) fluid
following exposure.3 Cysteinyl-leukotrienes (LTC4,
LTD4 and LTE4) mediate bronchoconstrictive re-
sponses in asthmatics, and drugs which block the
formation or the actions of cysteinyl-leukotrienes
(cys-LTs) are now used as treatment of asthma.9
There is also some evidence that anti-leukotriene
drugs may attenuate bronchial hyperresponsivenessin asthmatic subjects.10,11 The 5-lipoxygenase and
leukotriene biosynthesis inhibitor zileuton has been
shown to have anti-asthmatic effects and is
registered in the US for treatment of asthma.12
The present intervention study was initiated to
evaluate the involvement of leukotrienes in the
reactions that follow exposure in a swine house. In
view of the prominent neutrophilic response and
our earlier findings of increased levels of LTB4, we
attempted to obtain an overall inhibition of the
leukotriene pathway by treatment with zileuton
(Zyflos) prior to exposure. Urine was collected
before and after exposure for measurements of
urinary LTE4 and the concentrations of LTB4 and
LTE4 were measured in NAL fluids to determine the
drug effect on the leukotriene pathway. We also
investigated mast cell activation by measurements
of the mast cell marker 9a, 11b-PGF2. Influences on
cytokine and cell response in blood and NAL fluid
were monitored. The bronchial reactivity and the
levels of exhaled NO were measured before and
after exposure to evaluate any relation between
the 5-lipoxygenase inhibition, bronchial responsive-
ness and NO in the response to swine house dust.Material and methods
Subjects
Twenty-four (12 F/12M) healthy, non-smoking sub-
jects, with no history of allergic diseases, partici-
pated in the study. Mean age was 28 (range 20–47)
years in the placebo group and 26 (range 21–41)
years in the zileuton group. All subjects were
previously unexposed or only occasionally exposed
to farming environment and all participants gave
their informed consent. The study was approved by
the local ethics committee at Karolinska Institutet
(Dnr 99-463).
Study design
The study design is described in Fig. 1. At the first
visit, lung function and exhaled NO were measured,
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Figure 1 Study design. Twenty-three healthy subjects
treated with zileuton (n ¼ 11) or placebo (n ¼ 12) for 5
days prior to exposure in a swine house. NAL ¼ nasal
lavage, NO ¼ nitric oxide, PEF ¼ peak expiratory flow.
B.-M. Larsson et al.228a bronchial methacholine provocation test and a
NAL were performed. In addition, samples of blood
and urine were collected. At this occasion the
subjects were also randomised to treatment with
either zileuton (600mg) or equivalent placebo
capsules (qid) in a single blind manner. Twelve
subjects received placebo (4 F/8M) and 12 received
zileuton (8 F/4M). One subject (F) allocated to the
zileuton group decided to withdraw from the study
during the first day of treatment due to possible
drug-related urticaria.
Medications were continued for 5 days. After 4
days of medication subjects returned for blood and
urine sampling, another NAL and measurement of
exhaled NO, to test if basal levels were influenced
by the drug. The following day, the subjects were
exposed for 3 h while weighing pigs in a swine
confinement building holding about 300 pigs. The
subjects were instructed by a swine farmer to
shove the pigs into a weighing box. This is a quite
strenuous working situation associated with high
exposure levels to swine house dust. Six subjects,
three from each group, were exposed at each
occasion. Personal samplers were used to monitor
exposure levels throughout the whole exposure
period. Pre- and post-exposure, peak expiratory
flow (PEF) and body temperature were measured
and urine samples were collected. The measure-
ments and urine sampling were repeated approxi-
mately every second hour up to 5–6 h after the
exposure. The last medication capsule was taken
immediately after completion of the exposure.
Seven hours after the start of the exposure, NAL,
blood sampling, measurements of exhaled NO, lung
function and bronchial methacholine provocation
test were performed.
Exposure measurements
IOM filter cassettes (25mm) (SKC LTD, Dorset,
England) and plastic cyclones (25mm) (Casella
LTD, London, England) were used to monitorinhalable and respiratory dust levels, respectively.
Samplers were placed in the breathing zone on
subjects carrying personal samplers. Three to four
samplers were used for measurements of inhalable
and respirable dust levels, respectively. An average
value from each exposure occasion were calcu-
lated. The IOM cassettes were equipped with
polycarbonate filters (pore size 0.4 mm) (Nuclepore
Corp, Pleasanton, California, USA) for inhalable
dust sampling. For the respiratory fraction cellu-
lose filters (pore size 8 mm) (Millipore, Sundbyberg,
Sweden) were used for the gravimetric analysis and
polycarbonate filters (Nuclepore Corp; pore size
0.4 mm) for estimation of endotoxin concentrations.
Sampling was performed by portable pumps at
airflow of 1.9 to 2 l/min. The airflow was measured
before and after the sampling was completed and
an average value of the airflow was used for
calculation of sampled air volume. The filters were
conditioned 24 h prior weighing, using a Mettlers
ME22 balance (Mettler, Greisensee, Switzerland)
and reference filters. The filters used for endotoxin
analysis (polycarbonate) were extracted by rota-
tion in 10ml of endotoxin free water for 60min.
The extracts were centrifuged for 10min at 1000g
and the supernatant were frozen at 70 1C for later
analysis with a chromogen version of Limulus
amebocyte lysate assay (QCL-1000, Endotoxin,
BioWhittaker, Walkersville, USA, with Escherichia
coli 0111:B4 as standard).Registration of symptoms
In the morning, prior to the exposure, the subjects
filled in a questionnaire regarding symptoms (head-
ache, chills, mental fatigue, muscle pain and
nausea). This was repeated 8 h after the start of
the exposure. The symptoms were graded accord-
ing to a visual analogue scale (VAS) ranging from 0
to 100mm.Lung function and bronchial responsiveness
Lung function was measured with a wedge-spirom-
eter (Vitalographs, Buckingham, UK) according to
the American Thoracic Society criteria.16 The
highest of three measurements of FEV1 within 10%
and the highest of three slow and three forced vital
capacity (VC) manoeuvres were chosen as baseline
values. Local reference values were used.17,18 PEF
was measured using a peak flow meter (Mini-
Wright, Clement Clarke International Ltd, London,
UK).
Bronchial responsiveness was assessed by a
methacholine challenge, performed with inhalation
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Effects of 5-lipoxygenase inhibitor zileuton on airway responses 229of diluent followed by inhalation of increasing
doses of methacholine, starting at 0.5mg/ml, with
doubling concentration steps up to 32mg/ml.19 The
result is expressed as the cumulative dose causing a
20% decrease in FEV1 (PD20FEV1). Subjects, who had
not attained a 20% decrease in FEV1 when the
maximum dose (12.75mg) was reached, were
assigned a value (15mg) for the statistical analysis.
Exhaled nitric oxide
Exhaled NO were determined using single-breath
exhalations.20–22 To decrease contamination from
the oral cavity, mouthwash with sodium bicarbo-
nate (10%) in 1min preceded the measurement
procedure.23 The subjects inhaled NO-free air via a
mouthpiece to total lung capacity, followed im-
mediately by full exhalation, with a flow-rate of
about 100ml/s, through the mouthpiece into the
apparatus. During exhalation, an excess pressure
was created in the oral cavity, which ensures
closure of the velum and prevents contamination
of the sample with nasal air. NO was measured with
chemiluminescence after reaction with ozone
(Aerocrine NO-system type EBA:1, Aerocrine AB,
Stockholm, Sweden). The mean of three measure-
ments was used for evaluation.
NAL
NAL was performed using a procedure described by
Bascom and Pipkorn,24,25 with minor modifica-
tions.7 Briefly, 5ml sterile 0.9% NaCl was instilled
into one nostril using a needle-less syringe. After
10 s the fluid was expelled into a plastic cup. The
procedure was repeated in the other nostril and the
lavage samples were pooled. The cell concentra-
tion was counted in a Bu¨rker chamber. Cytospin-
prepared slides were stained with Hemacolour
(Mallinckrodt Baker B.V., Deventer, Holland) stain
and 300 cells were counted for cell differentials.
Less than 100 cells were considered as too few cells
to make an accurate differential count.
Peripheral blood
A total and differential white blood cell count of
peripheral blood was determined by flow cytometry
(FACSCalibur, Becton Dickinson, San Jose, CA, USA).
Blood was collected into EDTA and incubated with
cell surface markers CD45/CD14 (LeucoGateTM,
Becton Dickinson) in TRUECOUNTTM absolute count
tubes (Becton Dickinson) for 15min at room
temperature in darkness. The samples were then
haemolyszed using FACSTM Lysing Solution (BectonDickinson) and incubated for 15min at room
temperature in darkness and finally analysed by
flow cytometry.
Cytokine analyses in NAL and blood
Interleukin-6 (IL-6) in peripheral blood and NAL
fluid and IL-8 in NAL fluid were determined using a
specific ELISA validated in our laboratory26 using
commercially available antibody pairs (R&D sys-
tems, Europe, Abingdon, UK). The lower detection
limit was 3 ng/l for IL-6 and 50 ng/l for IL-8. For
duplicate samples an intra-assay coefficient of
variation (CV) of o10% and an inter-assay CV of
o20% was accepted. If the levels were below the
detection limit, the samples were assigned a value
(below the limit) for statistical analysis.
Measurements of LTB4, LTE4 and 9a,
11b-PGF2 in NAL and urine
Analysis of 9a, 11b-PGF2 and LTE4 in the urine, as
well as LTE4 and LTB4 in NAL fluid, were performed
without prior purification with enzyme immunoas-
says (Cayman Chemical, Ann Arbor, MI, USA) using
rabbit polyclonal anti-sera and acetylcholinester-
ase-linked tracers as described previously27,28 with
the following modifications. The LTE4 assay was
performed with a cysteinyl-leukotriene rabbit
polyclonal anti-serum with cross-reactivity to LTC4
(100%), LTD4 (100%) and LTE4 (67%). The standard
curve was set up with LTE4 as unlabelled ligand and
LTE4 linked to acetylcholinesterase was used as
tracer. Creatinine was determined in all urine
samples using a commercial available colorimetric
assay (Sigma Chemical Company, St Louis, MO,
USA). The results are expressed as ng per mmol of
creatinine or ng/mL for urine and NAL samples,
respectively. Regarding urine samples, the mean
value of two samples obtained in the afternoon on
the pre-exposure day were compared with the
mean of two samples obtained at the same time
points on the exposure day.
Statistics
Results are presented as median value (25th to 75th
percentiles) except for lung function data, oral
temperature and urinary levels of LTE4 and 9a, 11b-
PGF2, that are presented as mean value (95%
confidence interval). For all parameters except
LTB4 in NAL fluid, there was no statistically
significant difference between pre-medication and
pre-exposure values. Therefore, Wilcoxon’s signed
rank test was used for paired comparisons (pre- and
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were assessed by Mann–Whitney U-test. Student’s
t-test was used for analysis of lung function data,
oral temperature and symptom scores. Correlations
were estimated by Spearman Rank correlation test.
A P-valueo0.05 was considered significant.Results
Exposure measurements
The inhalable and respirable dust levels during the
exposure were 10 (9.7–16)mg/m3 and 0.73
(0.54–0.83)mg/m3, respectively. The correspond-
ing endotoxin concentration in inhalable dust and
respirable dust was 580 (360–830) and 39
(34–40) ng/m3.
Symptoms
The oral temperature in the morning prior to
exposure was 36.4 (36.0–36.8) 1C in zileuton trea-
ted subjects and 37.1 (36.5–37.7) 1C in the placebo
group (not statistically significant (ns)) and in-
creased after the exposure by 0.73 (0.10–1.35) 1C
(Po0:05) in the zileuton group and 0.41
(0.20–0.62) 1C (Po0:01) in the placebo group (ns
between groups). Chills increased after the ex-
posure in the zileuton group (Po0:01) but not in
the placebo group whereas headache increased in
both groups (Po0:05).
Lung function and bronchial responsiveness
FEV1 decreased slightly but significantly in both
groups following exposure, 7.2% in the placeboTable 1 Lung function before and after exposure to org
Pre-exposure
Placebo
FEV1 (l) 4.18 (3.74–4.6-2)
VC (l) 5.06 (4.48–5.65)
FEV1/VC (%) 83 (80–86)
PEF (l/min) 592 (545–638)
Zileuton
FEV1 (l) 3.77 (3.24–4.30)
VC (l) 4.38 (3.83–4.94)
FEV1/VC (%) 86 (82–90)
PEF (l/min) 544 (484–603)
There were no statistical significant differences between the grou
97% and 95% of predicted and basal VC was 95% and 91% of predigroup and 4.2% in the zileuton group compared with
pre-exposure values (Table 1). Vital capacity
decreased significantly in the placebo group
(2.8%, Po0:05), but not in the zileuton group
(1.8%). The bronchial responsiveness to methacho-
line increased in all subjects by 2.7 (1.6–4.2) and
1.9 (1.5–2.5) doubling concentration steps in the
placebo and zileuton group, respectively (Fig. 2).
There were no significant differences in the change
of lung function or bronchial responsiveness be-
tween the groups.
Leukotrienes in NAL and urine
The exposure increased urinary LTE4 levels in the
placebo group (Po0:05), but not in the zileuton
group (Fig. 3A). There was however, not a
statistically significant difference between the
groups. The medication did not influence baseline
LTE4 excretion in urine (data not shown).
The LTB4 level in NAL decreased during treat-
ment with zileuton (Po0:05) and remained un-
changed after the exposure. In the placebo group,
the LTB4 levels increased after the exposure
(Po0:05) with a significant difference compared
to the zileuton group (Po0:05, Fig. 4C, left panel).
Neither the medication with zileuton nor the
exposure affected the concentration of LTE4 in NAL
fluid (Fig. 4C, right panel).
9a, 11b-PGF2 in urine
Medication did not influence basal levels of 9a, 11b-
PGF2 in urine (data not shown). The excretion of
9a, 11b-PGF2 in urine increased in the placebo
group after the exposure (Fig. 3B, Po0:01), but not
in the group given zileuton (Po0:05 between
groups).anic dust (mean (95% confidence interval)).
Post-exposure P-value
3.88 (3.45–4.32) o0:001
4.92 (4.39–5.44) o0:05
79 (75–83) o0:05
505 (457–554) o0:001
3.61 (3.10–4.13) o0:01
4.30 (3.74–4.86) ns
84 (80–88) o0:01
495 (433–556) o0:001
ps, regarding pre- and post-exposure values. Basal FEV1 was
cted in the placebo and zileuton group, respectively.
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Figure 2 Bronchial responsiveness to methacholine before and after exposure in a swine confinement house in 12
healthy subjects treated with placebo and 10 healthy subjects treated with zileuton. The exposure induced a decrease
in PD20FEV1 in all subjects. Horizontal lines indicate median values. **Po0:01 for pre- and post-exposure comparisons.
Data from one subject was excluded from the statistical analysis due to a technical error during the methacholine
provocation test.
Figure 3 LTE4 (A) and 9, 11-PGF2 (B) and in urine samples collected from 11 subjects treated with zileuton and 12
subjects treated with corresponding placebo. Pre-exposure values are the mean value of two samples collected in the
afternoon the day before exposure. Post-exposure values are the mean of two samples collected in the afternoon after
the exposure. There was a significant difference between the groups regarding the change in concentration of 9, 11-
PGF2 (Po0:05) but not for LTE4. Mean (95% confidence interval) and individual values. *, Po0:05; **, Po0:01 for pre-
and post-exposure comparisons.
Effects of 5-lipoxygenase inhibitor zileuton on airway responses 231Exhaled nitric oxide
Exhaled nitric oxide was more than doubled in both
groups after exposure (Po0:01) and increased from
6.7 (4.3–11) to 14 (8.6–20) ppb in the zileuton
group and from 6.6 (5.6–8.3) to 14 (12–19) ppb in
the placebo group. There was no significant
difference between the groups.NAL
The cellular composition was not influenced by the
medication. Exposure caused a significant increase
of total cells in both groups (Po0:01, Fig. 4A) with
no difference between the groups. The increase
was mainly due to elevated numbers of neutrophilic
granulocytes (data not shown). No changes were
ARTICLE IN PRESS
Figure 4 Total cell concentration (A), the concentration of IL-6 and IL-8 (B) and the concentration of LTB4 and
LTEC4 (C), in NAL fluid before and after five days of medication and after exposure to swine dust. Open circles represent
placebo (n ¼ 12) and filled circles represent zileuton (n ¼ 11) treatment. Significant increases were observed in total
cell concentration and cytokine levels in both groups following exposure. LTB4 levels decreased after 5 days of zileuton
treatment, and were not further influenced by the exposure. The placebo group demonstrated significantly elevated
levels of LTB4 after exposure. Levels of LTE4 were not affected by drug pre-treatment or exposure. There were no
significant differences between the groups except for LTB4 (Po0:05). Median and interquartile range are presented.
*, Po0:05; **, Po0:01; ***, Po0:001 for pre- and post-exposure comparisons, # indicates significant differences
between the groups.
B.-M. Larsson et al.232observed concerning epithelial cells, monocytes,
lymphocytes, or eosinophilic and basophilic granu-
locytes. No correlation between increase in neu-
trophilic granulocytes and LTB4 was observed in the
placebo group (r ¼ 0:04, P ¼ 0:89).
The concentration of IL-6 in NAL fluid increased
in both groups following exposure to swine house
dust (Po0:01) with no statistically significant
difference between the two groups (Fig. 4B). The
exposure induced a significant increase in IL-8
concentration in NAL fluid in both groups (Fig.
4B), with no difference related to treatment. There
was no correlation between the increase inneutrophilic granulocytes and IL-8 (r ¼ 0:37, P ¼
0:27 for zileuton; r ¼ 0:04, P ¼ 0:89 for placebo).Peripheral blood
Treatment with zileuton or placebo did not influ-
ence the cellular composition in the peripheral
blood. After exposure the concentration of neu-
trophilic granulocytes and monocytes increased in
both groups (Po0:001, Fig. 5A). The increase in
neutrophils and monocytes was greater in zileuton-
treated subjects (Po0:05).
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(Fig. 5B, Po0:05 for placebo, Po0:01 for zileuton),
significantly more in the zileuton group (Po0:001).Discussion
The purpose of the study was to assess the
significance of leukotrienes in the mechanism
underlying the increase in bronchial responsiveness
induced by exposure in a swine confinement
facility. There are observations suggesting a role
for leukotrienes in increased bronchial responsive-
ness to other stimuli. For example, the cysLT1
receptor antagonists zafirlukast and montelukast
have both been found to reduce allergen-inducedFigure 5 Cellular reactions (A) and IL-6 (B) in peripheral blo
swine house dust. Open circles represent placebo (n ¼ 12) an
increase in concentration of neutrophils and monocytes di
increased significantly more in the zileuton group than in the
and filled zileuton. Median and interquartile range are prese
post-exposure comparisons, # indicates significant differenceairway hyperreactivity in atopic asthmatic sub-
jects.11,29 Furthermore, when zileuton (600mg qid)
was given as an add-on treatment to glucocorti-
costeroids, Dahle´n et al. reported a significantly
reduced bronchial responsiveness to histamine
after 6 weeks treatment in subjects with aspirin-
intolerant asthma.30 It has also been reported that
zileuton inhibited the response to cold dry air
challenge in asthmatic subjects in a fashion
suggesting a general effect on bronchial respon-
siveness.10 These effects of zileuton may support a
role for cysteinyl-leukotrienes, but may also in-
dicate participation of LTB4 in bronchial inflamma-
tion induced by different stimuli.
In the present study of healthy, non-allergic
subjects, we were, however, not able to demon-
strate any influence of zileuton treatment on theod before, and during medication and after exposure to
d filled circles represent zileuton (n ¼ 11) treatment. The
ffered significantly between the groups (Po0:05). IL-6
placebo group (Po0:001). Open circles represent placebo
nted. *, Po0:05; **, Po0:01; ***, Po0:001 for pre- and
s between the groups.
ARTICLE IN PRESS
B.-M. Larsson et al.234increased bronchial responsiveness induced by the
swine dust exposure. We cannot conclude whether
our finding implicate that leukotrienes are not
involved in the mechanisms underlying increased
bronchial responsiveness in this particular model,
or if the treatment period (5 days) and/or the dose
(600mg qid) were inadequate to produce major
inhibition of leukotriene formation. Measurements
of urinary LTE4 excretion would seem to support the
latter alternative, as there was no significant
difference in neither post-medication nor post-
exposure urinary LTE4 between placebo and active
treatment. However, as urinary LTE4 increased
significantly post-exposure only in the placebo
group but not in the zileuton group, the findings
suggests a partial inhibitory effect on cys-LTs
formation.
We found a post-exposure increase in LTB4 in NAL
fluid in the placebo group, but not in subjects
treated with zileuton. The finding supports a
significant inhibitory effect of zileuton on local
leukotriene biosynthesis in the nasal cavity. The
results may indicate that local LTB4 production is
inhibited by zileuton more easily than is whole-
body formation of cys-LTs, as reflected by the
measurements of urinary excretion of LTE4. This
view is supported by a previous study of Hui et al. in
patients with atopic asthma. They found that a
single dose of zileuton (800mg) almost totally
blocked the ex vivo formation of LTB4 in whole
blood, whereas allergen-induced urinary excretion
of LTE4 was only reduced to about 50% in the same
subjects, in association with a non-significant
effect on the bronchoconstriction.31 In line with
this, in our study zileuton only caused a threshold
inhibition of systemic leukotriene biosynthesis, but
had a clear-cut effect on local production in
particular of LTB4. A complete inhibition of leuko-
trien formation is needed before it can be
concluded that leukotrienes are not involved in
the increased bronchial responsiveness induced by
exposure to swine house dust.
The dose of zileuton that was used in the study is
established to have clinical anti-asthmatic effect.
It is however known, that exposure to a swine
house environment represents a very strong pro-
inflammatory stimulus. For example, a more than
70-fold increase of the concentration of neutro-
philic granulocytes is demonstrated in bronchoal-
veolar lavage fluid from healthy subjects 24 h after
3 h of exposure in a swine confinement building.6,7
We therefore speculate that the degree of enzyme
inhibition needs to be larger in this particular
model than in chronic asthma. It is established that
the enzymes in the leukotriene pathway may be up-
regulated.32 Therefore, it is not unlikely that theenzymes in the biosynthetic pathway may become
up-regulated during the course of this exposure to
many aggressive factors such as endotoxin and
bacterial peptidoglycans.7,33 Furthermore, little is
known about how large inhibition of, for example,
urinary LTE4 that is required for clinical efficacy. In
studies where clinical improvements have been
documented, the inhibition of urinary LTE4 has
been about 50%.30,34
The present study confirmed our previous indica-
tions that mast cells are activated following the
exposure as increased urinary levels of the PGD2
metabolite 9a, 11b-PGF2 were detected.
3 The post-
exposure urinary excretion of 9a, 11b-PGF2 was
lower in the group treated with zileuton. Although
the limited effect of zileuton on systemic leuko-
triene production calls for cautious interpretation
of the finding, the decreased levels of 9a, 11b-PGF2
were observed both within the group and between
the placebo and zileuton group. As zileuton has no
direct effect on the cyclooxygenase,35 this raises
the hypothesis that 5-lipoxygenase products some-
how are involved in mast cell activation or
recruitment during this particular reaction. This
may be a general mechanism as release of tryptase
has been reported to be inhibited by zileuton in
NALs collected after aspirin challenge of aspirin-
intolerant asthmatics.36
Further support for mast cell activation following
exposure in this farming environment comes from a
previous study where pre-medication with sodium
cromoglycate attenuated the inflammatory re-
sponse after exposure to swine house dust in
healthy subjects, with reduced post-exposure
increases of neutrophils, TNF-a and IL-6 levels in
bronchoalveolar lavage fluid.37 The mechanism of
action of sodium cromoglycate includes stabilisa-
tion of the mast cell and inhibition of mediator
release.38 Since TNF-a is a typical mast cell
cytokine39 and the TNF-a response was almost
abolished by cromoglycate treatment,37 these
results strengthen the hypothesis that mast cells
are involved in the inflammatory response after
exposure to swine house dust. Despite these
inhibitory effects of cromoglycate on cytokine
generation in this particular model, cromoglycate
did not significantly inhibit the increase in bron-
chial responsiveness following the exposure.37 As
cromoglycate and zileuton otherwise both are
effective against many common triggers of asthma,
we conclude that pharmacological intervention to
modify the increased bronchial responsiveness
following swine house exposure may require fairly
aggressive treatments. In order to study underlying
mechanisms in a broader perspective, it would be
interesting to combine different asthma drugs,
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order to see if additive or synergistic effects are
obtained.
In the present study, post-exposure blood con-
centration of neutrophils and monocytes was
significantly higher in subjects treated with zileu-
ton compared to placebo. The symptom scores for
chills increased significantly only in zileuton-trea-
ted subjects and this could possibly have been
related to the higher serum levels of the pro-
inflammatory cytokine IL-6, which is involved in the
induction of fever reactions.40 The explanation to
these findings is not clear, but suggests that
leukotrienes and/or other 5-lipoxygenase products
might have anti-inflammatory properties as well.
One such group of compounds is the lipoxins, which
have inhibitory effects on neutrophil activation.41
It has been shown that lipoxin A4 inhibits the IL-1b-
induced IL-6 and IL-8 response in human synovial
fibroblasts.42 The possibility that the 5-lipoxygen-
ase in the current exposure model induces the
formation of both pro- and anti-inflammatory
endogenous substances would in addition make
the effect of 5-lipoxygenase inhibition more com-
plex to evaluate, and may contribute to the limited
effects we observed with zileuton on the main
endpoints. One explanation could be that lipoxins
on the one hand, and the cysteinyl-leukotrienes on
the other, have opposing actions and that selective
intervention with a cysLT1 receptor antagonist is
required to affect bronchial responsiveness.
Increased levels of exhaled NO after exposure
using this particular model, have been demon-
strated in an earlier study,43 and were also
confirmed in the present study. In fact, the NO
levels were increased to the same magnitude (two-
fold) as has been measured in moderate asthma
using a similar method for measurements.44 The NO
response was not modified by the treatment with
zileuton. As discussed, this may either reflect
insufficient inhibition of leukotrienes or that
leukotrienes are not directly involved in the NO
formation, which is indicated by a study where
asthmatic subjects displayed no change in NO levels
after inhalation of LTE4.
45 On the other hand, there
are studies suggesting direct relations between
leukotrienes and airway generation of NO. For
example, 2 weeks of treatment with montelukast
reduced the exhaled NO in asthmatic children by
20%46 and in adult asthmatics pranlukast inhibited
the increase in exhaled NO when the use of high-
dose corticosteroid was reduced by half.47 The
present study included healthy non-asthmatic sub-
jects and the mechanisms responsible for induction
of NO synthesis might also differ between normal
and asthmatic subjects.In summary, we failed to achieve significant
inhibition of bronchial responsiveness and urinary
leukotriene excretion after exposure in a swine
confinement house following 5 days pre-treatment
with the clinically used dose of the 5-lipoxygenase
inhibitor zileuton. One conclusion from this finding
is that the inflammatory response in this specific
model is different, complex and more difficult to
inhibit than common asthmatic reactions.
Moreover, the study reinforces the concept that
swine house dust induced airway inflammation is
fundamentally different from common asthmatic
reactions. The observed failure of zileuton, an
established anti-asthmatic drug, to inhibit the
reaction, adds yet another asthma medication that
is ineffective in this model. If this profile of drug-
resistant bronchial hyperresponsiveness relates to
the induced neutrophilic airway inflammation, the
model may have relevance also for studies of
mechanisms in chronic bronchitis and COPD.Acknowledgements
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